Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 2, 1992 - Issue 12
Journal homepage
7
Views
0
CrossRef citations to date
0
Altmetric
Cardiovascular Agents (Including Blood Products)

Overview: The Atrial Peptide System as a Therapeutic Target

Thomas W von Geldern Cardiovascular Research, Abbott Laboratories, Abbott Park, IL, 60064, USA
Pages 2087-2101 | Published online: 02 Mar 2011

References to Primary Literature

  • Wendt, R Silver, P Dinish, J Metz, N Michalak, R Todt, J Lappe, R Pharmacology of a synthetic human atrial natriuretic factor, Wy-47,663 Biologically Active Atrial Peptides. Raven Press New York 1987 330–334.
  • Lappe, R Todt, J Effects of atrial natriuretic factor on vascular reactivity Biological and Molecular Aspect of Atrial Factors. Alan R Liss Inc New York 1988 161–171.
  • Lappe, R Todt, J Anaritide. Drugs of the Future 1989 14 936–938.
  • Opgenorth, T Budzik, G Mollison, K Davidsen, S Holst, M Holleman, W Atrial peptides induce mast cell histamine release. Peptides 1990 11 1003–1007.
  • Hulks, G Thomson, N Inhaled atrial natriuretic peptide and asthmatic airways. Brit. Med. J. 1992 304 1156.
  • Shionoiri, H Oda, H Yasuda, G Takasaki, I Kato, Y Goto, H Diuretic effects of intranasal and intrarectal administration of rat atrial natriuretic factor in anesthetized spontaneously hypertensive rats. Curr. Ther. Res. 1987 42 1189–1193.
  • Delabays, A Porchet, M Waeber, B Nussberger, J Brunner, H Effects of intranasal administration of synthetic (4–28) human atrial natriuretic peptide to normal volunteers. J. Cardiovasc. Pharmacol. 1989 13 173–176.
  • Maack, T Suzuki, M Almeida, F Nussenzweig, D Scarborough, R McEnroe, G Lewicki, J Physiological role of silent receptors of atrial natriuretic factor. Science 1987 238 675–678.
  • Dimaio, J Jaramillo, J Wernic, D Grenier, L Welchner, E Adams, J Synthesis and biological activity of atrial natriuretic factor analogues: Effect of modifications to the disulfide bridge. J. Med. Chem. 1990 33 661–667.
  • Wernic, D Dimaio, J Adams, J Enantiospecific synthesis of L-aminosuberic acid. Synthetic applications in preparation of atrial natriuretic factor analogues. J. Org. Chem. 1989 54 4224–4228.
  • Williams, T Nutt, R Brady, S Lyle, T Ciccarone, T Colton, C Palaveda, W Smith, G Veber, D Winquist, R Very active ANF analogs with implications for a bioactive conformation Peptides: Chemistry, Structure and Biology. ESCOM Leiden 1990 258–259.
  • Nutt, R Ciccarone, T Brady, S Colton, C Williams, T Winquist, R Veber, D ANF analogs designed to exhibit increased metabolic stability Peptide Chemistry 1987. Protein Research Foundation Osaka 1988 501–506.
  • Rockway, T Connolly, P Devine, E Budzik, G Thomas, A Kiso, Y Holleman, W Structure-activity relationships in atrial natriuretic factor (ANF) agonists Peptides: Chemistry, Structure, and Biology. ESCOM The Netherlands 1990 244–246.
  • Rockway, T Budzik, G Bush, E Connolly, P Davidsen, S Devine, E Lucas, S Von Geldern, T Holleman, W Small atrial natriuretic factor (ANF) peptide analogs maintaining agonist activity Peptides: Chemistry, Structure, and Biology. ESCOM The Netherlands 1990 252–253.
  • Von Geldern, T Rockway, T Davidsen, S Budzik, G Bush, E Chu-Moyer, M Devine, E Holleman, W Johnson, M Lucas, S Pollock, D Smital, J Thomas, A Opgenorth, T Small atrial natriuretic peptide analogues: Design, synthesis, and structural requirements for guanylate cyclase activation. J. Med. Chem. 1992 35 808–816.
  • Scarborough, R Schenk, D McEnroe, G Arfsten, A Kang, L Schwartz, K Lewicki, J Truncated atrial natriuretic peptide analogs. J. Biol. Chem. 1986 261 12960–12964.
  • Bovy, P O'Neal, J Olins, G Patton, D Identification of structural requirements for analogues of atrial natriuretic peptide (ANP) to discriminate between receptor subtypes. J. Med. Chem. 1989 32 869–874.
  • Holleman, W Budzik, G Devine, E Pollock, D Opgenorth, T Thomas, A Von Geldern, T Rockway, T Truncated atrial natriuretic factor analogs retain full agonist activity. Can. J. Physiol. Pharm. 1991 69 1622–1627.
  • Pollock, D Opgenorth, T Beneficial effect of the atrial natriuretic factor analog A68828 in postischemic acute renal failure. J. Pharmacol. Exp. Ther. 1990 255 1166–1169.
  • Pollock, D Holst, M Opgenorth, T Effect of the ANF analog A68828 in cisplatin-induced acute renal failure. J. Pharmacol. Exp. Ther. 1991 257 1179–1183.
  • Ortola, F Ballerman, B Anderson, S Mendez, R Brenner, B Elevated plasma atrial natriuretic peptide levels in diabetic rats: Potential mediator of hyperfiltration. J. Clin. Invest. 1987 80 670–674.
  • Abell, T Richards, A Yandle, T Espiner, E Frampton, C Ikram, H Competitive peptide antagonists of ANF-induced cyclic guanosine monophosphate production. Biochem. Biophys. Res. Commun. 1989 164 108–113.
  • Kitajima, Y Minamitake, M Furuya, M Takehisa, M Katayama, T Tanake, S Linear α-human atrial natriuretic peptide analogs display receptor binding activity and inhibit α-hANP-induced cGMP accumulation. Biochem. Biophys. Res. Commun. 1989 164 1295–1301.
  • Von Geldern, T Budzik, G Dillon, T Holleman, W Holst, M Kiso, Y Novosad, E Opgenorth, T Rockway, T Thomas, A Yeh, S Atrial natriuretic peptide antagonists: Biological evaluation and structural correlations. Mol. Pharmacol. 1990 38 771–778.
  • Delport, C Winand, J Poloczek, P Von Geldern, T Christophe, J Discovery of a potent atrial natriuretic peptide antagonist for ANPA receptors in the human neuroblastoma NB-OK-1 cell line. Eur. J. Pharmacol. in press.
  • Norling, L Von Geldern, T Thornhill, B Chevalier, R Atrial natriuretic peptide analog (A71915) acts as an inhibitor of ANP-stimulated guanylyl cyclase in rat glomeruli. Clin. Res. 1992 40 N2 A386.
  • Okwueze, M Von Geldern, T Opgenorth, T Vari, R Effects of ANP blockade on glomerular hyperfiltration during onset of IDDM in BB/DP rats. Clin. Res. 1991 39 N4 A848.
  • Webber, W Fischli, W Hochuli, E Kupfer, E Weibel, E Anantin - A peptide antagonist of the atrial natriuretic factor (ANF). I. Producing organism, fermentation, isolation and biological activity. J. Antibiotics 1991 44 164–171.
  • Wyss, D Lahm, H Manneberg, M Labhardt, A Anantin - A peptide antagonist of the atrial natriuretic factor (ANF). II Determination of the primary sequence by NMR on the basis of proton assignments. J. Antibiotics 1991 44 172–180.
  • Morishita, Y Sano, T Ando, K Saitoh, A Kase, H Yamada, K Matsuda, Y Microbial polysaccharide, HS-142–1, competitively and selectively inhibits ANP binding to its guanylyl cyclase-containing receptor. Biochem. Biophys. Res. Commun. 1991 176 949–957.
  • Morishita, Y Sano, T Kase, H Yamada, K Inagami, T Matsuda, Y HS-142–1, a novel nonpeptide atrial natriuretic peptide (ANP) antagonist, blocks ANP-induced renal responses through a specific interaction with guanylyl cyclase-linked receptors. Eur. J. Pharmacol. 1992 225 203–207.
  • Sano, T Morishita, Y Matsuda, Y Yamada, K Pharmacological profile of HS-142–1, a novel nonpeptide atrial natriuretic peptide antagonist of microbial origin. I. Selective inhibition of the actions of natriuretic peptides in anesthetized rats. J. Pharmacol. Exp. Ther. 1992 260 2 825–831.
  • Sano, T Morishita, Y Yamada, K Matsuda, Y Effects of HS-142–1, a novel non-peptide ANP antagonist, on diuresis and natriuresis induced by acute volume expansion in anesthetized rats. Biochem. Biophys. Res. Commun. 1992 182 824–829.
  • Almeida, F Suzuki, M Scarborough, R Lewicki, J Maack, T Clearance function of type C receptors of atrial natriuretic factor in rats. Am. J. Physiol. 1989 256 R469–R475 ( Regulatory Integrative Comp. Physiol. 25).
  • Crane, A Dodd, S Dolamore, P Kitchin, J Louttit, J Pipe, A Ross, B Seale, P Ward, P Wise, H Structure-activity relationships of some synthetic atrial natriuretic peptide analogues. Biochem. Soc. Trans. 1990 1320–1321 ( Peptide & Protein Group).
  • Kenny, A Stephenson, S Role of endopeptidase 24.11 in the inactivation of atrial natriuretic peptide. FEBS Lett. 1988 232 1–8.
  • Olins, G Spear, K Siegel, N Zurcher-Neely, H Inactivation of atrial natriuretic factor by the renal brush border. Biochim. Biophys. Acta 1987 901 97–100.
  • Adams, S Fok, K Olins, G Trapani, A Krieter, P Tjoeng, F McMahon, E Blaine, E Biological and Molecular Aspects of Atrial Natriuretic Factor UCLA Symposium 1988.
  • Berman, J Pelton, J Hassman, C Buck, S Shea, P Ertl, P Heminger, E Broersma, R Synthesis and activity of partial retro-inverse modified atrial natriuretic factor analogs. Int. J. Peptide Protein Res. 1988 32 47–55.
  • Berman, J Chen, T Sargent, R Buck, S Shea, P Heminger, E Broersma, R Design and synthesis of metabolically stable atrial natriuretic factor analogs. FEBS Lett. 1988 237 76–80.
  • Devine, E Buko, A Cepa, S Davidsen, S Holleman, W Marselle, C Opgenorth, T Rockway, T Von Geldern, T HPLC and PDMS analysis of cleavage products aid in the design of small, stable ANP analogues. Int. J. Peptide Protein Res. 1992 In press.
  • Webb, R Yasay, G McMartin, C McNeal, R Zimmerman, M Degradation of atrial natriuretic peptide: Pharmacologic effects of protease EC 24.11 inhibition. J. Cardiovascular Pharmacol. 1989 14 285–293.
  • Richards, A Wittert, G Espiner, E Yandle, T Frampton, C Ikram, H Prolonged inhibition of endopeptidase 24.11 in normal man: Renal, endocrine and haemodynamic effects. J. Hypertens. 1991 9 955–962.
  • Valentin, J Qiu, C Wiedemann, E Gardner, D Humphreys, M Inhibition of neutral endopeptidase amplifies the effects of endogenous atrial natriuretic peptide on blood pressure and fluid partition. Am. J. Hypertens. 1992 5 88–91.
  • Roques, B Fournie-Zaluskie, M Soroca, E Lecomte, J Malfroy, B Llorens, C Schwartz, J The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature (London) 1980 288 286–288.
  • Seymour, A Swerdel, J Fennell, S Druckman, S Neubeck, R Delaney, N Potentiation of the depressor responses to atrial natriuretic peptides in conscious SHR by an inhibitor of neutral endopeptidase. J. Cardiovascular Pharmacol. 1989 14 194–204.
  • Seymour, A Fennell, S Swerdel, J Potentiation of the renal effects of atrial natriuretic factor (99–126) by SQ 29,072. Hypertension Dallas 1989 14 87–97.
  • Seymour, A Norman, J Asaad, M Fennell, S Little, D Kratunis, V Rogers, W Anti-hypertensive and renal activity of SQ 28,603, an inhibitor of neutral endopeptidase. J. Cardiovascular Pharmacol. 1991 17 296–304.
  • Margulies, K Cavero, P Seymour, A Delaney, N Burnett, J Neutral endopeptidase inhibition potentiates the renal actions of atrial natriuretic factor. Kidney Int. 1990 38 67–72.
  • Seymour, A Abboa-Offei, B Asaad, M Rogers, W Evaluation of SQ 28,603, an inhibitor of neutral endopeptidase, in conscious monkeys. Can. J. Physiol. Pharm. 1991 69 1609–1617.
  • Cavero, P Margulies, K Winaver, J Seymour, A Delaney, N Burnett, J Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation 1990 82 196–201.
  • Lecomte, J Baumer, P Lim, C Duchier, J Cournot, A Dussaule, J Ardaillou, R Gros, C Chaignon, B Sougue, A Schwartz, J Stereoselective protection of exogenous and endogenous atrial natriuretic factor by enkephalinase inhibitors in mice and humans. Eur. J. Pharmacol. 1990 179 65–73.
  • Kahn, J Patey, M Dubois-Rande, J Merlet, P Castaigne, A Lim-Alexandre, C Duboc, D Gros, C Schwartz, J Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet 1990 335 118–119.
  • Lefrancois, P Clerc, G Duchier, J Lim, C Lecomte, J Gros, C Schwartz, J Antihypertensive activity of sinorphan ‘letter’. Lancet 1990 336 307–308.
  • Haslanger, M Sybertz, E Neustadt, B Smith, E Nechuta, T Berger, T Carboxyalkyl dipeptides with atrial natriuretic factor potentiating and antihypertensive activity. J. Med. Chem. 1989 32 737–739.
  • Sybertz, E Chiu, P Vemulapalli, S Pitts, B Foster, C Watkins, R Barnett, A Haslanger, M SCH 39370, a neutral met-alloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycortico-sterone-sodium hypertensive rats. J. Pharmacol. Exp. Ther. 1989 250 624–631.
  • Helin, K Tikkanen, I Tikkanen, T Saiionmaa, O Sybertz, E Vemulapalli, S Sariola, F Fyhrquist, F Prolonged neutral endopeptidase inhibition in heart failure. Eur. J. Pharmacol. 1991 198 23–30.
  • Vemulapalli, S Chiu, P Brown, A Griscti, K Sybertz, E The blood pressure and renal responses to SCH 34826, a neutral met-alloendopeptidase inhibitor, and C-ANF (423) in DOCA-salt hypertensive rats. Life Sciences 1991 49 383–391.
  • Sybertz, E Chiu, P Vemulapalli, S Watkins, R Haslanger, M Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826: An orally active neutral met-alloendopeptidase inhibitor. Hypertension 1990 15 152–161.
  • Monopoli, A Ongini, E Cigola, E Olivetti, G The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. J. Cardiovascular Pharmacol. 1992 20 496–504.
  • Burnier, M Ganslmayer, M Perret, F Porchet, M Kosoglou, T Golud, A Nussberger, J Waeber, B Brunner, H Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers. Clin. Pharmacol. Ther. 1991 50 181–191.
  • Hirsch, A Creager, M Roddy, M Dzau, V Renal hemodynamic, natriuretic and hormonal effects of neutral endopeptidase inhibitor SCH 34826 in patients with mild heart failure. Circulation 1991 84 Supp II 959.
  • Danilewicz, J Barclay, P Barnish, I Brown, D Campbell, S James, K Samuels, G Terrett, N Wythes, M UK-69,578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic. Biochem. Biophys. Res. Commun. 1989 164 l 58–65.
  • Barclay, P Bennett, J Samuels, G Shepperson, N The atriopeptidase inhibitor (±)can-doxatrilat reduces the clearance of atrial natriuretic factor in both intact and nephrectomized rats: Evidence for an extrarenal site of action. Biochem. Pharmacol. 1991 41 841–844.
  • Northbridge, D Jardine, A Alabaster, C Barclay, P Connell, J Dargie, H Dilly, S Findlay, I Lever, A Samuels, G Effects of UK 69578, a novel atriopeptidase inhibitor. Lancet 1989 2 591–593.
  • Richards, A Wittert, G Crozier, I Espiner, E Yandle, T Ikram, H Inhibition of endopeptidase 24.11 in essential hypertension: Hemodynamic and hormonal effects. Circulation 1991 84 Supp II 433.
  • Bevan, E Connell, J Doyle, J Carmichael, H Davies, D Lorimer, A McInnes, G Can-doxatril, a neutral endopeptidase inhibitor: Efficacy and tolerability in essential hypertension. J. Hypertens. 1992 10 607–613.
  • Reigger, G Kahles, H Ferstl, B Kromer, E Kochsiek, K Acute effects of atriopeptidase inhibitor UK 79 300 in patients with chronic congestive heart failure. Circulation 1989 80 Supp II 111.
  • Chiu, P Tetzloff, G Romano, M Foster, C Sybertz, E Influence of C-ANF receptor and neutral endopeptidase on pharmacokinetics of ANF in rats. Am. J. Physiol. 1991 260 R208–R216 ( Regulatory Integrative Comp. Physiol. 29).
  • Wilkins, M Settle, S Kirk, J Taylor, S Moore, K Unwin, R Response to atrial natriuretic peptide, endopeptidase 24.11 inhibitor and C-ANP receptor ligand in the rat. Br. J. Pharmacol. 1992 107 50–57.
  • Bovy, P O'Neal, J Olins, G Patton, D Mehta, P McMahon, E Palomo, M Schuh, J Blehm, D A synthetic linear decapeptide binds to the atrial natriuretic peptide receptors and demonstrates cyclase activation and vasorelaxant activity. J. Biol. Chem. 1989 264 20309–20313.

References

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.